Late-breaking data show an aspirin-free medication regimen benefits people with abbott's heartmate 3™ heart pump

New data from the aries trial show for the first time that an aspirin-free regimen can improve outcomes for people living with the heart pump by reducing hospitalizations without increasing the risk of blood clots more than 30,000 people worldwide have received abbott's life-saving heart pump to overcome advanced heart failure abbott park, ill., nov. 13, 2023 /prnewswire/ -- abbott (nyse: abt) announced new late-breaking data that show advanced heart failure patients living with its heartmate 3™ heart pump who didn't receive aspirin as part of their blood-thinning medication regimen experienced fewer complications from bleeding and were associated with reduced hospital visits compared to patients who took aspirin daily following their implant.
ABT Ratings Summary
ABT Quant Ranking